Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

BACKGROUND: Immune-related enterocolitis (irEC) is the most common serious complication from checkpoint inhibitors (CPIs). The current front-line treatment for irEC, high-dose corticosteroids (CS), have significant side effects and prolonged therapy may reduce CPI-anti-tumor activity. Early addition...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Daniel H, Zobniw, Chrystia M, Trinh, Van A, Ma, Junsheng, Bassett, Roland L, Abdel-Wahab, Noha, Anderson, Jaime, Davis, Jennifer E, Joseph, Jocelyn, Uemura, Marc, Noman, Ali, Abu-Sbeih, Hamzah, Yee, Cassian, Amaria, Rodabe, Patel, Sapna, Tawbi, Hussein, Glitza, Isabella C, Davies, Michael A, Wong, Michael K, Woodman, Scott, Hwu, Wen-Jen, Hwu, Patrick, Wang, Yinghong, Diab, Adi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180568/
https://www.ncbi.nlm.nih.gov/pubmed/30305177
http://dx.doi.org/10.1186/s40425-018-0412-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180568/
https://www.ncbi.nlm.nih.gov/pubmed/30305177
http://dx.doi.org/10.1186/s40425-018-0412-0

Ejemplares similares